Hospital
Community Health Center of Branch County
Community Health Center of Branch County was paid $11.80M by Medicaid between Jan 2018 and Dec 2024, across 204 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoCOMMUNITY HEALTH CENTER OF BRANCH COUNTY
COLDWATER, MI 49036
COLDWATER, MI 49036
33aNPI1063471639assigned 03/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.80M
24GClaims333,240
24DCodes billed204
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#60 of 86
Median peer was paid$21.55M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,534 | $1.55M | |
| 2019 | 45,803 | $1.38M | |
| 2020 | 35,471 | $1.29M | |
| 2021 | 47,577 | $1.93M | |
| 2022 | 45,641 | $1.79M | |
| 2023 | 52,432 | $2.04M | |
| 2024incomplete | 52,782 | $1.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 20,433 | 19,330 | $2.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 11,359 | 10,687 | $2.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,006 | 3,765 | $1.23M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.8% | 7,622 | 7,046 | $682K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.8% | 9,636 | 9,194 | $681K |
| G0378 | Hospital observation service, per hour | 3.9% | 1,110 | 1,025 | $457K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 2,732 | 2,662 | $407K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 3,880 | 2,788 | $348K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 13,281 | 3,938 | $325K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 4,451 | 3,536 | $262K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 7,981 | 6,588 | $251K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 2,073 | 1,968 | $198K |
192 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 6,621 | $182K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,928 | $171K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,553 | $165K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 4,127 | $148K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 4,104 | $146K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 81 | $117K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,206 | $102K |
| 80061 | Lipid panel | <1% | 4,373 | $74K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,374 | $67K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,053 | $66K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 903 | $51K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,984 | $49K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,478 | $45K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 201 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 22,504 | $38K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 772 | $38K |
| 97162 | <1% | 656 | $35K | |
| 86900 | <1% | 1,244 | $30K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,635 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,677 | $26K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,039 | $25K |
| 97161 | <1% | 489 | $25K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,452 | $24K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,686 | $23K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,686 | $23K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 160 | $19K |
| 76801 | <1% | 302 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $17K |
| 72100 | <1% | 493 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,262 | $16K |
| 81514 | <1% | 150 | $15K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 366 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,247 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 684 | $12K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 96 | $12K |
| 73562 | <1% | 956 | $12K | |
| 73630 | <1% | 1,562 | $12K | |
| 97597 | <1% | 170 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 120 | $11K |
| 73610 | <1% | 1,271 | $10K | |
| 74018 | <1% | 515 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,285 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,364 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,175 | $9K |
| 73030 | <1% | 668 | $9K | |
| 73130 | <1% | 1,021 | $9K | |
| 96367 | <1% | 263 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 128 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 104 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 18 | $7K |
| 84439 | <1% | 1,864 | $6K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $6K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 55 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 455 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $5K |
| 73110 | <1% | 529 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,295 | $5K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 317 | $5K |
| 59025 | Fetal non-stress test | <1% | 58 | $5K |
| 85027 | <1% | 2,633 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 187 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,660 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 365 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 63 | $4K |
| 84702 | <1% | 1,958 | $4K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 62 | $3K |
| 82607 | <1% | 479 | $3K | |
| 86780 | <1% | 395 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 202 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 254 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $2K |
| 82043 | <1% | 828 | $2K | |
| 80055 | <1% | 108 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 70 | $2K |
| 82570 | <1% | 825 | $2K | |
| 83735 | <1% | 4,772 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $2K |
| 83880 | <1% | 959 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 743 | $2K |
| 85610 | <1% | 2,851 | $2K | |
| 71250 | <1% | 26 | $2K | |
| 93017 | <1% | 67 | $1K | |
| 82728 | <1% | 217 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 568 | $1K |
| 86140 | <1% | 2,161 | $1K | |
| 87077 | <1% | 692 | $1K | |
| 72110 | <1% | 60 | $1K | |
| 87150 | <1% | 73 | $1K | |
| 86803 | <1% | 147 | $931.68 | |
| 87340 | <1% | 255 | $891.88 | |
| 80076 | <1% | 730 | $859.24 | |
| 87186 | <1% | 601 | $804.48 | |
| 93971 | <1% | 14 | $757.40 | |
| 83540 | <1% | 265 | $732.75 | |
| 86703 | <1% | 115 | $728.96 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 39 | $726.21 |
| 81001 | <1% | 7,476 | $716.41 | |
| 87081 | <1% | 578 | $675.28 | |
| 87510 | <1% | 138 | $590.98 | |
| 87480 | <1% | 138 | $590.98 | |
| 76642 | <1% | 12 | $583.83 | |
| 73560 | <1% | 65 | $569.10 | |
| 73502 | <1% | 43 | $566.65 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 399 | $564.19 |
| 83550 | <1% | 135 | $559.65 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,257 | $558.66 |
| 83690 | <1% | 5,863 | $535.46 | |
| 82950 | <1% | 213 | $471.82 | |
| 87660 | <1% | 138 | $440.10 | |
| 73080 | <1% | 53 | $435.68 | |
| 87070 | <1% | 414 | $423.74 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $420.55 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18 | $337.42 |
| 85730 | <1% | 1,689 | $328.63 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 865 | $324.68 |
| 86762 | <1% | 83 | $308.85 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 37 | $307.09 |
| 81003 | <1% | 4,263 | $282.21 | |
| 85007 | <1% | 444 | $262.46 | |
| 73590 | <1% | 25 | $254.61 | |
| 81025 | <1% | 6,417 | $248.23 | |
| 83655 | <1% | 31 | $248.06 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 304 | $246.39 |
| 73140 | <1% | 19 | $245.52 | |
| 85652 | <1% | 470 | $240.03 | |
| 80306 | <1% | 511 | $194.89 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 789 | $192.37 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,638 | $173.64 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 43 | $171.12 |
| 86308 | <1% | 190 | $168.76 | |
| 87807 | <1% | 405 | $168.46 | |
| 85379 | <1% | 1,084 | $158.81 | |
| 97116 | <1% | 21 | $147.96 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $142.01 |
| 84484 | <1% | 4,945 | $129.40 | |
| 82150 | <1% | 1,038 | $120.82 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 426 | $113.33 |
| 73090 | <1% | 31 | $96.28 | |
| 87040 | <1% | 677 | $92.30 | |
| 87503 | <1% | 864 | $91.83 | |
| 86850 | <1% | 1,024 | $89.71 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 230 | $86.11 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 47 | $71.85 |
| 86901 | <1% | 1,299 | $38.36 | |
| 82550 | <1% | 426 | $37.50 | |
| 84146 | <1% | 14 | $36.54 | |
| 87400 | <1% | 483 | $30.12 | |
| 82077 | <1% | 1,052 | $24.58 | |
| 83605 | <1% | 1,945 | $24.22 | |
| 88304 | <1% | 36 | $22.75 | |
| 87205 | <1% | 45 | $19.43 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,817 | $12.00 |
| 82962 | <1% | 71 | $1.67 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 20 | $0.72 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 545 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 160 | $0.00 |
| 96376 | 0% | 2,037 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 177 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,124 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 46 | $0.00 |
| J3490 | Unclassified drugs | 0% | 97 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 401 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 534 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 2,260 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 90 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 304 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 468 | $0.00 |
| 12001 | 0% | 76 | $0.00 | |
| 87430 | 0% | 425 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 544 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 152 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 147 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 24 | $0.00 |
| A9270 | Non-covered item or service | 0% | 17 | $0.00 |
| 80143 | 0% | 227 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 84 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 447 | $0.00 |
| 80179 | 0% | 222 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,487 | $0.00 |
| 94664 | 0% | 262 | $0.00 | |
| 82010 | 0% | 36 | $0.00 | |
| 90715 | 0% | 209 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 27 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 555 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 171 | $0.00 |
| 87210 | 0% | 40 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 97 | $0.00 |
| 82800 | 0% | 15 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| 82140 | 0% | 16 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARP, KEVIN (VP REV CYCLE)
| Provider | Location | Paid |
|---|---|---|
| The Toledo Hospital | Toledo, OH | $151.22M |
| Emma L. Bixby Medical Center | Adrian, MI | $18.35M |
| Bay Park Community Hospital | Oregon, OH | $16.39M |
| Defiance Hospital INC. | Defiance, OH | $11.55M |
| Memorial Hospital | Fremont, OH | $11.40M |
| Fostoria Hospital Association | Fostoria, OH | $7.48M |
| Toledo Hospital | Toledo, OH | $2.38M |
| Herrick Memorial Hospital, INC. | Tecumseh, MI | $1.82M |
| Flower Hospital | Sylvania, OH | $368K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.